View Item 

Show simple item record

La prevención de la influenza: recomendaciones para la temporada de 2005-2006

dc.contributor.authorLe Riverend, Eloísaes_ES
dc.date.accessioned2015
dc.date.available2015
dc.date.issued2005es_ES
dc.identifier.citationLe Riverend, Eloísa (2005) La prevención de la influenza: recomendaciones para la temporada de 2005-2006. Rev Panam Salud Publica;18(3) 210-215,set. 2005. Retrieved from http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892005000800012&lng=pt&nrm=iso&tlng=eses_ES
dc.identifier.urihttp://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892005000800012&lng=pt&nrm=iso&tlng=eses_ES
dc.identifier.urihttps://iris.paho.org/handle/10665.2/8042
dc.format.extenttabes_ES
dc.relation.ispartofseriesRev Panam Salud Publica;18(3),sept. 2005es_ES
dc.subjectInfluenza Humanaes_ES
dc.subjectGuias de Prática Clínica como Assuntoes_ES
dc.subjectComitês Consultivospt_BR
dc.subjectAntiviraises_ES
dc.subjectTransmissão de Doença Infecciosapt_BR
dc.subjectTransmissão Vertical de Doença Infecciosapt_BR
dc.subjectInfecções por HIVpt_BR
dc.subjectPessoal de Saúdept_BR
dc.subjectPrioridades em Saúdept_BR
dc.subjectVírus da Influenza Aes_ES
dc.subjectVírus da Influenza Aes_ES
dc.subjectVírus da Influenza Bes_ES
dc.subjectVírus da Influenza Bes_ES
dc.subjectVacinas contra Influenzapt_BR
dc.subjectVacinas contra Influenzapt_BR
dc.subjectVacinas contra Influenzapt_BR
dc.subjectVacinas contra Influenzapt_BR
dc.subjectInfluenza Humanaes_ES
dc.subjectInfluenza Humanaes_ES
dc.subjectInfluenza Humanaes_ES
dc.subjectLactaçãopt_BR
dc.subjectDoenças Profissionaispt_BR
dc.subjectSeleção de Pacientespt_BR
dc.subjectFatores de Riscopt_BR
dc.subjectViagemes_ES
dc.subjectEstados Unidoses_ES
dc.subjectVacinaçãopt_BR
dc.subjectVacinaçãopt_BR
dc.subjectVacinas Atenuadaspt_BR
dc.subjectVacinas Atenuadaspt_BR
dc.subjectVacinas Atenuadaspt_BR
dc.subjectVacinas de Produtos Inativadospt_BR
dc.titleLa prevención de la influenza: recomendaciones para la temporada de 2005-2006es_ES
dc.title.alternativePreventing influenza: recommendations for the 2005-2006 seasones_ES
dc.typeJournal articlesen_US
dc.rights.holderPan American Health Organizationen_US
dc.description.notesInfluenza is a serious health problem worldwide due to the epidemics and pandemics that it periodically causes. The Advisory Committee on Immunization Practices (ACIP) of the United States of America recently published updated recommendations for influenza prevention and control for the 2005-2006 season. Many of these guidelines are of interest to the countries of the Region of the Americas, particularly those related to vaccination, which is the mainstay for preventing and controlling this disease. Various changes have been made in the recommendations that were published in 2004. First, the ACIP recommends vaccination against influenza for persons with any condition (e.g., cognitive dysfunction, spinal cord injury, seizure disorder, or other neuromuscular disorder) that can compromise respiratory function or make eliminating respiratory secretions difficult or that can increase the risk for aspiration. Second, the ACIP strongly recommends that all health care workers be vaccinated against influenza annually and encourages facilities that employ health care workers to vaccinate them by using approaches that maximize immunization rates. Third, the ACIP encourages the use of both available vaccines (inactivated and live, attenuated influenza vaccine (LAIV)) for eligible persons every influenza season, especially persons in recommended target groups. When inactivated virus vaccine is in short supply, the use of LAIV is especially encouraged, if feasible, for eligible persons (including health care workers) because such use might considerably increase the availability of inactivated virus vaccine for persons in high-risk groups. Fourth, the 2005-06 trivalent vaccine virus strains are A/California/7/2004 (H3N2)-like, A/New Caledonia/20/99 (H1N1)-like, and B/Shanghai/361/2002-like antigens. For the A/California/7/2004 (H3N2)-like antigen, manufacturers may use the antigenically equivalent A/ New York/55/2004 virus, and for the B/Shanghai/361/2002-like antigen, manufacturers may use the antigenically equivalent B/Jilin/20/2003 virus or B/Jiangsu/10/2003 virus. (AU)en_US


Files in this item

Thumbnail
Name:
27674.pdf
Size:
66.99Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record